The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
After ZW171's exit, ZW251 enters the clinic.
The company is to test its KLK2-targeting pasritamig in a late-line setting.
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.
